NASDAQ: NVCR
Novocure Ltd Stock Forecast, Predictions & Price Target

Analyst price target for NVCR

Based on 5 analysts offering 12 month price targets for Novocure Ltd

Min Forecast
$17.00+5.92%
Avg Forecast
$25.20+57.01%
Max Forecast
$52.00+223.99%

Should I buy or sell NVCR stock?

Based on 5 analysts offering ratings for Novocure Ltd.

Hold
Strong Buy
0 analysts 0%
Buy
2 analysts 40%
Hold
3 analysts 60%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NVCR stock forecasts and price targets.

NVCR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-24
lockedlocked$00.00+00.00%2026-07-23
lockedlocked$00.00+00.00%2026-07-13
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-05-01

1 of 1

Forecast return on equity

Is NVCR forecast to generate an efficient return?

Company
68.51%
Industry
21.77%
Market
178.03%
NVCR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVCR forecast to generate an efficient return on assets?

Company
29.13%
Industry
14.01%
NVCR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVCR earnings per share forecast

What is NVCR's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.14
Avg 3 year Forecast
-$0.74

NVCR revenue forecast

What is NVCR's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$737.7M+5.5%
Avg 2 year Forecast
$907.1M+29.74%
Avg 3 year Forecast
$949.8M+35.84%
NVCR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVCR revenue growth forecast

How is NVCR forecast to perform vs Medical Devices companies and vs the US market?

Company
11.57%
Industry
7.65%
Market
13.78%
NVCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVCR vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NVCR$16.05$25.20+57.01%Hold
ALMR$28.35$30.75+8.47%Strong Buy
INSP$60.09$59.85-0.41%Hold
BFLY$8.42$5.75-31.71%Strong Buy
ATEC$9.57$16.77+75.22%Strong Buy

Novocure Stock Forecast FAQ

Is Novocure Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: NVCR) stock is to Hold NVCR stock.

Out of 5 analysts, 0 (0%) are recommending NVCR as a Strong Buy, 2 (40%) are recommending NVCR as a Buy, 3 (60%) are recommending NVCR as a Hold, 0 (0%) are recommending NVCR as a Sell, and 0 (0%) are recommending NVCR as a Strong Sell.

If you're new to stock investing, here's how to buy Novocure stock.

What is NVCR's earnings growth forecast for 2026-2028?

(NASDAQ: NVCR) Novocure's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 23.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.

Novocure's earnings in 2026 is -$148,565,000.On average, 9 Wall Street analysts forecast NVCR's earnings for 2026 to be -$180,689,010, with the lowest NVCR earnings forecast at -$203,128,123, and the highest NVCR earnings forecast at -$133,155,818. On average, 9 Wall Street analysts forecast NVCR's earnings for 2027 to be -$132,806,481, with the lowest NVCR earnings forecast at -$170,034,216, and the highest NVCR earnings forecast at -$46,345,444.

In 2028, NVCR is forecast to generate -$86,111,699 in earnings, with the lowest earnings forecast at -$132,375,631 and the highest earnings forecast at -$56,243,341.

What is NVCR's revenue growth forecast for 2026-2028?

(NASDAQ: NVCR) Novocure's forecast annual revenue growth rate of 11.57% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Novocure's revenue in 2026 is $699,193,000.On average, 9 Wall Street analysts forecast NVCR's revenue for 2026 to be $85,899,767,251, with the lowest NVCR revenue forecast at $80,851,840,087, and the highest NVCR revenue forecast at $90,111,613,284. On average, 9 Wall Street analysts forecast NVCR's revenue for 2027 to be $105,630,350,381, with the lowest NVCR revenue forecast at $88,582,679,405, and the highest NVCR revenue forecast at $171,990,505,680.

In 2028, NVCR is forecast to generate $110,599,094,374 in revenue, with the lowest revenue forecast at $99,281,723,184 and the highest revenue forecast at $123,898,373,760.

What is NVCR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NVCR) forecast ROA is 29.13%, which is higher than the forecast US Medical Devices industry average of 14.01%.

What is NVCR's Price Target?

According to 5 Wall Street analysts that have issued a 1 year NVCR price target, the average NVCR price target is $25.20, with the highest NVCR stock price forecast at $52.00 and the lowest NVCR stock price forecast at $17.00.

On average, Wall Street analysts predict that Novocure's share price could reach $25.20 by Jul 24, 2027. The average Novocure stock price prediction forecasts a potential upside of 57.01% from the current NVCR share price of $16.05.

What is NVCR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NVCR) Novocure's current Earnings Per Share (EPS) is -$1.30. On average, analysts forecast that NVCR's EPS will be -$1.55 for 2026, with the lowest EPS forecast at -$1.74, and the highest EPS forecast at -$1.14. On average, analysts forecast that NVCR's EPS will be -$1.14 for 2027, with the lowest EPS forecast at -$1.46, and the highest EPS forecast at -$0.40. In 2028, NVCR's EPS is forecast to hit -$0.74 (min: -$1.14, max: -$0.48).

What is NVCR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NVCR) forecast ROE is 68.51%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.